Refine by
Vaccine Product Articles & Analysis
67 news found
As reported by UCLA Health, a novel cancer vaccine could trigger robust immune responses in patients with pancreatic and colorectal cancer, driving a growing wave of research excitement around cancer vaccines. ...
The BOC Sciences team will showcase its cutting-edge products and services at booth #937. TIDES USA 2024 is to be held in Boston from May 14 to 17, 2024, gathering industry leaders across the biotechnology and pharmaceutical landscape. ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its comprehensive portfolio of ELISA Based Assays for vaccine development and bioprocess applications. Vaccine development involves a variety of assays to support vaccine research and development, from early ...
In the face of global health crises such as the COVID-19 pandemic, the development and production of vaccines have become paramount to safeguarding public health and restoring normalcy. ...
Our bioproduction technology will help mass produce long, GMP-grade mRNA in a cost-efficient and scalable fashion by leveraging processes in engineered living cells. By bringing down the production cost of mRNA and simplifying the supply chain to make it local and more resilient, bYoRNA will help make mRNA vaccines available to the population of emerging ...
After years of efforts on research and innovation, we are now able to provide a wide range of vaccine development services as well, in addition to a diversified offering of vaccine products,” said the marketing chief of Alfa Chemistry. The featured vaccine products supplied by Alfa Chemistry are listed as below: ...
Viral vaccine manufacturing is a complex venture with the main steps being antigen production, purification and formulation. ...
ByNuvonis
Nuvonis is providing 100 MCB vials to its clients allowing for production of very large quantities of WCB vials. Out of one MCB vial, 500 – 1,000 vials of WCB cells can be easily produced (Fig.). ...
ByNuvonis
Tune into this free webinar to learn about: AAV biology and its use in cell and gene therapies State-of-the-art production of cell and gene therapies Current process intensification methods: cell line and vector engineering, media optimization, and bioreactor design to increase yields New strategies to properly attenuate anti-viral defences in the ...
I am excited to join the team at Scandinavian Biopharma, an expanding company with an interesting product portfolio and a vaccine candidate with such an importance in people’s lives. ...
In this role, you will lead the planning, execution and documentation of clinical studies for our late clinical phase vaccine products. Join us in our work to give people worldwide a longer and better life. We are an entrepreneurial company and experts in global vaccine development, manufacturing, registration and commercialisation of ...
IRVINE, Calif. – OCT. 4, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma (GBM) study which demonstrates enhanced progression-free survival (PFS). The publication, titled “Enhanced Progression-Free Survival in ...
Having proven our capability, we now take this next important step as we aim to drive production of Element i+® analyzers and cartridges at scale and to accelerate key test menu expansion, such as our recently announced Nu.Q® Vet Cancer Screen, cCRP, SDMA, infectious diseases, and more, in single and multi-plex formats that are substantially better than the competition. ...
In the double-blind, randomized Phase 2 trial, 145 subjects ages 19.5-82.5 years received one of three formulations of the personalized dendritic cell-lymphocyte product, then were assessed for safety and cellular response. All three formulations of the vaccine were well-tolerated with no high-grade or serious adverse events reported. ...
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, has now expanded lipid system portfolio and launched a series of Sphingolipids products to support customers' scientific research. ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, and University of Antwerp today announce that they have entered into a collaboration agreement to research and develop a ...
About Dynavax Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the ...
About Dynavax Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, today announced that preclinical data from ZIP1642, its COVID-19 vaccine candidate, was published in the ...
AAV vectors are the delivery vehicle of choice for inserting therapeutic genes into cells, but increasing production yields of these biopharmaceuticals in sufficient quantities to meet demand is challenging. ...